Danaher Co. (NYSE:DHR) Shares Purchased by Flagship Harbor Advisors LLC

Flagship Harbor Advisors LLC lifted its holdings in Danaher Co. (NYSE:DHR) by 1.1% during the second quarter, Holdings Channel reports. The fund owned 8,783 shares of the conglomerate’s stock after buying an additional 97 shares during the quarter. Flagship Harbor Advisors LLC’s holdings in Danaher were worth $2,108,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in DHR. Moneta Group Investment Advisors LLC grew its position in Danaher by 96,490.5% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 23,287,013 shares of the conglomerate’s stock valued at $6,180,839,000 after buying an additional 23,262,904 shares during the period. Norges Bank acquired a new stake in Danaher during the fourth quarter valued at $2,057,164,000. CIBC Private Wealth Group LLC grew its position in Danaher by 98.8% during the fourth quarter. CIBC Private Wealth Group LLC now owns 4,364,999 shares of the conglomerate’s stock valued at $1,158,558,000 after buying an additional 2,169,134 shares during the period. Geode Capital Management LLC grew its position in Danaher by 14.3% during the fourth quarter. Geode Capital Management LLC now owns 12,774,623 shares of the conglomerate’s stock valued at $3,384,177,000 after buying an additional 1,595,344 shares during the period. Finally, Generation Investment Management LLP acquired a new stake in Danaher during the first quarter valued at $374,240,000. Institutional investors and hedge funds own 76.71% of the company’s stock.

Insiders Place Their Bets

In other Danaher news, SVP Jose-Carlos Gutierrez-Ramos sold 590 shares of Danaher stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $250.54, for a total transaction of $147,818.60. Following the transaction, the senior vice president now directly owns 6,939 shares of the company’s stock, valued at $1,738,497.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Danaher news, EVP Joakim Weidemanis sold 22,439 shares of Danaher stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $263.42, for a total transaction of $5,910,881.38. Following the completion of the sale, the executive vice president now directly owns 88,689 shares in the company, valued at $23,362,456.38. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Jose-Carlos Gutierrez-Ramos sold 590 shares of Danaher stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $250.54, for a total transaction of $147,818.60. Following the sale, the senior vice president now owns 6,939 shares of the company’s stock, valued at $1,738,497.06. The disclosure for this sale can be found here. Insiders have sold 47,922 shares of company stock valued at $12,552,233 over the last ninety days. Company insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Stifel Nicolaus dropped their price target on shares of Danaher from $250.00 to $240.00 and set a “hold” rating on the stock in a research report on Wednesday, July 26th. Bank of America lifted their target price on shares of Danaher from $250.00 to $280.00 in a research report on Wednesday, July 26th. StockNews.com started coverage on shares of Danaher in a research report on Tuesday, September 12th. They issued a “hold” rating on the stock. Raymond James lifted their target price on shares of Danaher from $270.00 to $290.00 and gave the company an “outperform” rating in a research report on Wednesday, July 26th. Finally, Barclays lifted their target price on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research report on Tuesday, July 25th. Five investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $289.79.

Danaher Stock Performance

NYSE:DHR opened at $255.25 on Monday. The company’s 50-day moving average price is $253.41 and its 200-day moving average price is $245.09. The company has a current ratio of 2.08, a quick ratio of 1.70 and a debt-to-equity ratio of 0.35. The company has a market cap of $188.46 billion, a P/E ratio of 29.96, a P/E/G ratio of 2.72 and a beta of 0.80. Danaher Co. has a twelve month low of $221.22 and a twelve month high of $283.63.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 25th. The conglomerate reported $2.05 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.04. Danaher had a net margin of 20.95% and a return on equity of 15.03%. The company had revenue of $7.16 billion for the quarter, compared to the consensus estimate of $7.12 billion. During the same period in the previous year, the firm earned $2.76 earnings per share. Danaher’s quarterly revenue was down 7.7% compared to the same quarter last year. On average, sell-side analysts forecast that Danaher Co. will post 8.84 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Thursday, October 12th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.42%. The ex-dividend date is Wednesday, October 11th. Danaher’s dividend payout ratio (DPR) is presently 12.68%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions.